Form 4: Ventas CFO Sells Shares Under Pre-Arranged 10b5-1 Plan
Insider Transaction Report
Ventas' Executive Vice President and CFO, Robert F. Probst, reported the sale of 29,930 shares and withholding of 2,275 shares for taxes on January 2, 2026.
Summary
- Robert F. Probst, Executive Vice President and Chief Financial Officer of Ventas, Inc. (VTR), reported stock transactions on January 2, 2026.
- Probst sold 29,930 shares of Ventas common stock at a weighted average price of $77.2532 per share.
- This sale was conducted pursuant to a Rule 10b5-1 trading plan that Probst entered into on February 19, 2025.
- Additionally, 2,275 shares were withheld to cover tax obligations related to the vesting of restricted stock units, which were granted on March 19, 2025, at a price of $77.33 per share.
- Following these transactions, Probst directly beneficially owns 136,159 shares of Ventas, Inc. common stock.
Sentiment
Score: 5
Explanation: Neutral. The transaction is a pre-planned insider sale, which is a routine disclosure. While insider selling can sometimes be viewed negatively, the 10b5-1 plan mitigates concerns about opportunistic timing, suggesting the sale is not based on new, adverse information.
Negatives
- The sale of 29,930 shares by a key executive, even if pre-planned, could be perceived as a slight negative signal by some investors, although the Rule 10b5-1 plan mitigates concerns about opportunistic timing.
Future Outlook
The filing does not provide any forward-looking statements or guidance regarding Ventas, Inc.'s future performance or strategic direction.
Industry Context
This Form 4 filing details an insider transaction, which is a standard regulatory disclosure for publicly traded companies. It does not offer specific insights into broader industry trends within the healthcare REIT sector or competitive dynamics.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Disclosure | Disclosure of stock transactions by a key executive (EVP and CFO) as required by Section 16(a) of the Securities Exchange Act of 1934, demonstrating compliance with regulatory transparency requirements. | January 2, 2026 | Enhances transparency for shareholders regarding executive stock movements, which is a core aspect of good corporate governance. |
| Power of Attorney Grant | Robert F. Probst granted power of attorney to Carey S. Roberts, Kevin Bohl, Kenneth Hagan, Jessica Stricklin, and Jose Torres for the purpose of executing and filing SEC Forms 3, 4, 5, and 144. | December 10, 2025 | Streamlines the process for timely and accurate SEC filings by the reporting person, ensuring efficient compliance with regulatory obligations. |
Stakeholder Impact
- Shareholders: Provides transparency regarding an executive's stock transactions, which can inform investment decisions and perceptions of management alignment.
- Regulatory Authorities: Demonstrates compliance with SEC reporting requirements for insider trading, upholding market integrity.
Key Dates
| Date | Description |
|---|---|
| February 19, 2025 | Date Robert F. Probst entered into the Rule 10b5-1 trading plan. |
| March 19, 2025 | Date restricted stock units were granted to Robert F. Probst under the Ventas, Inc. 2022 Incentive Plan. |
| December 10, 2025 | Date Robert F. Probst signed the Power of Attorney for SEC filings. |
| January 2, 2026 | Date of reported stock transactions (sale of shares and shares withheld for taxes). |
| January 6, 2026 | Date the Form 4 was signed by Robert F. Probst's attorney-in-fact. |
Keywords
Ventas, VTR, Robert F. Probst, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CFO, Healthcare REIT
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.